Compare Quest Diagnostics Inc (DGX) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Annaly Capital Management, Inc. — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Annaly Capital Management, Inc. trades at $23.04 (market cap $16.86B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Annaly Capital Management, Inc. pays the higher dividend (13.04%). Which is the better fit depends on your goals.
| DGX | NLY | |
|---|---|---|
Market Cap | $22.80B | $16.86B |
Sector | Health | Financials |
52-Week High | $216.02 | $24.40 |
52-Week Low | $166.42 | $19.47 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | 13.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
NLY trades at $22.53, down 1.44% on the day, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. The stock shows a P/E of 7.27 and P/B of 1.14, trading below the consensus price target of $24.40. Recent news highlights earnings growth potential and a dividend of $0.75 payable in July 2026, supported by a net income margin of 91.17% in 2025.
Outlook remains positive with analyst consensus favoring Buy ratings (57%), though risks include interest rate sensitivity and high leverage. The stock offers value with earnings momentum, but investors should monitor debt levels and Federal Reserve policy impacts on mortgage REITs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
